Oncomine Focus Panel PDL1: Comprehensive Cancer Biomarker Analysis
Understanding the Oncomine Focus Panel PDL1 Test
The Oncomine Focus Panel PDL1 represents a cutting-edge approach to cancer diagnostics, combining advanced genetic sequencing with protein expression analysis. This comprehensive test provides oncologists with critical information needed to develop personalized treatment strategies for cancer patients. By simultaneously analyzing multiple biomarkers through next-generation sequencing (NGS) and immunohistochemistry (IHC), this test offers a complete picture of a tumor’s molecular profile.
What Makes This Test Essential for Cancer Care?
Modern cancer treatment has evolved beyond traditional chemotherapy and radiation. Today, targeted therapies and immunotherapies offer more precise treatment options with potentially fewer side effects. The Oncomine Focus Panel PDL1 serves as a crucial tool in identifying which patients are most likely to benefit from these advanced treatments by analyzing specific genetic mutations and immune checkpoint markers.
What the Test Measures and Detects
The Oncomine Focus Panel PDL1 provides comprehensive analysis across multiple dimensions:
Genetic Alterations (NGS Component)
- 52 cancer-related genes analyzed for mutations
- Gene fusions and rearrangements
- Copy number variations and amplifications
- Single nucleotide variants (SNVs)
- Insertions and deletions (indels)
Protein Expression (IHC Component)
- PDL1 protein expression levels
- Tumor proportion score (TPS)
- Combined positive score (CPS)
- Immune cell infiltration assessment
Who Should Consider This Test?
The Oncomine Focus Panel PDL1 is particularly valuable for patients with:
Specific Cancer Types
- Non-small cell lung cancer (NSCLC)
- Melanoma
- Bladder cancer
- Head and neck cancers
- Renal cell carcinoma
- Gastric cancer
- Other solid tumors being considered for immunotherapy
Clinical Scenarios
- Newly diagnosed cancer patients seeking targeted therapy options
- Patients with advanced or metastatic disease
- Individuals who have failed conventional treatments
- Patients being considered for clinical trials
- Those seeking second opinions on treatment options
Benefits of Taking the Oncomine Focus Panel PDL1 Test
Personalized Treatment Planning
This test provides oncologists with detailed molecular information that can guide treatment selection, potentially avoiding ineffective therapies and their associated side effects.
Immunotherapy Eligibility Assessment
The PDL1 component specifically helps determine whether patients are likely to respond to immune checkpoint inhibitors, which have revolutionized cancer treatment for many patients.
Comprehensive Biomarker Analysis
By analyzing multiple biomarkers simultaneously, this test provides a more complete picture than single-gene tests, potentially identifying multiple treatment options.
Clinical Trial Matching
The comprehensive genetic profile can help identify patients who may qualify for specific clinical trials based on their tumor’s molecular characteristics.
Understanding Your Test Results
Genetic Alteration Report
Your results will include detailed information about detected genetic mutations, their clinical significance, and potential targeted therapy options. Each identified alteration will be classified according to established guidelines for therapeutic relevance.
PDL1 Expression Interpretation
The PDL1 results will indicate the level of protein expression, typically reported as Tumor Proportion Score (TPS) or Combined Positive Score (CPS). Higher scores generally correlate with better response to immunotherapy treatments.
Clinical Actionability
Results will be accompanied by information about FDA-approved therapies matching your specific genetic profile, as well as potential clinical trial options and emerging treatment strategies.
Test Pricing and Availability
| Test Component | Price (USD) |
|---|---|
| Discount Price | $1312 |
| Regular Price | $1750 |
| Turnaround Time | 20-25 days |
| Sample Type | Tumor tissue (paraffin embedded blocks) |
Nationwide Testing Availability
We have testing facilities and partner locations across the United States, including major metropolitan areas such as New York, Los Angeles, Chicago, Houston, Phoenix, Philadelphia, San Antonio, San Diego, Dallas, and San Jose. Our network ensures that patients nationwide can access this advanced cancer diagnostic testing.
Important Pre-Test Information
The Oncomine Focus Panel PDL1 requires a doctor’s prescription for testing. Please note that prescriptions are not applicable for surgery and pregnancy cases, or for individuals planning to travel abroad. Our team will work with your healthcare provider to ensure proper sample collection and processing.
Take the Next Step in Your Cancer Care Journey
Don’t leave your treatment decisions to chance. The Oncomine Focus Panel PDL1 provides the comprehensive molecular information needed to make informed decisions about your cancer treatment. With our discounted price of $1312 USD, advanced cancer diagnostics are more accessible than ever.
Ready to get started? Call or WhatsApp us today at +1(267) 388-9828 to schedule your test or speak with our genetic counseling team.
Our experienced staff is available to answer your questions, help coordinate testing with your healthcare provider, and ensure you receive the comprehensive cancer care you deserve. Take control of your treatment journey with the power of precision medicine.
